Subscribe to RSS
DOI: 10.1055/s-2008-1077725
© Georg Thieme Verlag KG Stuttgart · New York
Invisible gastric carcinoma detected by random biopsy: long-term results after photodynamic therapy
Publication History
submitted 24 April 2008
accepted after revision 1 October 2008
Publication Date:
13 November 2008 (online)
![](https://www.thieme-connect.de/media/endoscopy/200811/lookinside/thumbnails/10.1055-s-2008-1077725-1.jpg)
Background and study aims: Gastric cancer diagnosed from routine gastric biopsies without any evidence of a visible lesion and negative repeated biopsies is an infrequent but serious clinical problem for which gastrectomy has usually been recommended, even if operative specimens do not show cancer either. We report on a series of 22 such patients undergoing long-term follow-up after attempted treatment with photodynamic therapy (PDT).
Patients and methods: 22 patients with invisible gastric cancer (IGC) who presented during a 10-year period (10 men, mean age 56 ± 15 years) were prospectively included. Initial histopathological findings confirmed by second opinion included 10 well-differentiated adenocarcinomas and 12 signet ring cell carcinomas. After two negative state-of-the art endoscopic reassessments, a single session of PDT using 5-delta-aminolevulinic acid (ALA) was performed in the area from which the biopsy was taken, and patients were followed up regularly.
Results: After a mean follow-up period of 56.2 ± 27.6 months, three patients had died of causes unrelated to gastric cancer, four had developed mucosal cancer that was successfully treated endoscopically after 4 – 38 months, and the remaining 15 patients remained without evidence of recurrent gastric cancer, lymph-node involvement, or metastases during a follow-up period of 54 ± 26 months.
Conclusions: Our results suggest that gastrectomy may not be the only option for IGC, which might follow an uneventful natural course provided careful follow-up is scheduled. The role of PDT in this setting remains unclear and should be studied further.
References
- 1 Cadman B, Dixon M F, Wyatt J I. Value of routine, non-targeted biopsies in the diagnosis of gastric neoplasia. J Clin Pathol. 1997; 50 832-834
- 2 McCulloch P. The role of surgery in patients with advanced gastric cancer. Best Pract Res Clin Gastroenterol. 2006; 20 767-787
- 3 Ell C, Gossner L, May A. et al . Photodynamic ablation of early cancers of the stomach by means of mTHPC and laser irradiation: preliminary clinical experience. Gut. 1998; 43 345-349
- 4 Pech O, Nagy C D, Gossner L. et al . Photodynamic therapy of human Barrett’s cancer using 5-aminolaevulinic acid-induced protoporphyrin IX: an in-vivo dosimetry study in athymic nude mice. Eur J Gastroenterol Hepatol. 2002; 14 657-662
- 5 Pech O, Gossner L, May A. et al . Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett’s cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc. 2005; 62 24-30
- 6 Loh C S, MacRobert A J, Buonaccorsi G. et al . Mucosal ablation using photodynamic therapy for the treatment of dysplasia: an experimental study in the normal rat stomach. Gut. 1996; 38 71-78
- 7 Tan W C, Krasner N, O’Toole P, Lombard M. Enhancement of photodynamic therapy in gastric cancer cells by removal of iron. Gut. 1997; 41 14-18
- 8 Gossner L, Stolte M, Sroka R. et al . Photodynamic ablation of high-grade dysplasia and early cancer in Barrett’s esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998; 114 448-455
- 9 Gossner L, May A, Sroka R, Ell C. A new through-the-scope balloon applicator for photodynamic therapy in the esophagus and cardia. Endoscopy. 1999; 31 370-376
-
10 Yoshino J, Matsui T.
Natural course of early cancer. Gastric cancer. In: Fujita R, Jass JR, Kaminishi M, Schlemper RJ, eds Early cancer of the gastrointestinal tract: endoscopy, pathology, and treatment. Tokyo; Springer 2006: 223-228 - 11 Forman D, Burley V J. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006; 20 633-649
- 12 Berrino F. The EUROCARE study: strengths, limitations, and perspectives of population based, comparative survival studies. Ann Oncol. 2003; 14 (Suppl 5) 9-13
- 13 Tsukuma H, Oshima A, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut. 2000; 47 618-621
- 14 Gotoda T. Endoscopic resection of early gastric cancer: the Japanese perspective. Curr Opin Gastroenterol. 2006; 20 561-569
- 15 Hyung W J, Noh S H, Lee J H. et al . Early gastric carcinoma with signet ring cell histology. Cancer. 2002; 94 78-83
- 16 Alberts B. Molecular biology of the cell, 3rd edn. New York; Garland Publishing, Inc 1994: 1255-1291
- 17 Vollmers H P, Brändlein S. The “early birds”: natural IgM antibodies and immune surveillance. Histol Histopathol. 2005; 20 927-937
- 18 Vollmers H P, Dämmrich J, Ribbert H. et al . Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer. 1995; 76 550-558
C. EllMD, PhD
Department of Medicine II
Dr Horst-Schmidt-Kliniken Wiesbaden
Ludwig-Erhard-Strasse 100
65199 Wiesbaden
Germany
Fax: +49-611-432418
Email: thomas.rabenstein@hsk-wiesbaden.de